Drug Profile
Compound 1416
Alternative Names: Compound 1416Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Nanjing University
- Developer Nanjing EffecttPharm Drug Development Corporation
- Class Antineoplastics
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for clinical-Phase-Unknown development in Cancer(Adjunctive treatment) in China
- 01 Jul 2016 Clinical trials in Cancer (Adjunctive treatment) in China (unspecified route)